| 技术与方法 |
|
|
|
|
| 一种新型高糖基化免疫融合蛋白NESP-Fc的研制 |
| 晏丽, 王康, 李瑞建, 白义, 白先宏, 周海平 |
| 百泰生物药业有限公司 北京 100176 |
|
| Manufaction of a New High-glycosylated Fusion Protein NESP-Fc |
| YAN Li, WANG Kang, LI Rui-jian, BAI Yi, BAI Xian-hong, ZHOU Hai-ping |
| BioTech Pharmaceuticals Co., Ltd., Beijing 100176, China |
引用本文:
晏丽, 王康, 李瑞建, 白义, 白先宏, 周海平. 一种新型高糖基化免疫融合蛋白NESP-Fc的研制[J]. 中国生物工程杂志, 2015, 35(4): 80-85.
YAN Li, WANG Kang, LI Rui-jian, BAI Yi, BAI Xian-hong, ZHOU Hai-ping. Manufaction of a New High-glycosylated Fusion Protein NESP-Fc. China Biotechnology, 2015, 35(4): 80-85.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20150412
或
https://manu60.magtech.com.cn/biotech/CN/Y2015/V35/I4/80
|
|
[1] McClellan W M, Flanders W D, Langston R D, et al. Anemia and renal insufficiency are independent risk factors for death among patients with congesture heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol, 2002, 13(7):1928-1936.
[2] Fisher S, Roheim P S. Role of liver in the inactivation of erythropoietin. Nature,1963,30(200):899-900.
[3] Koury M J, Bondurant M C. Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells. J Cell Physiol, 1988, 137(1):65-74.
[4] Pljesa S. Possible complications of erythropoietin therapy in patients with chronic renal failure. Med Pregl, 2004, 57(5-6):254-257.
[5] Egrie J C, Browne J K. Development and characterization of novel erythropoiesis stimulating protein(NESP). Br J Cancer, 2001, 84(suppl 1):3-10.
[6] Macdougall I C. An overview of the efficacy and safety of novel erythropoiesis stimulating protein(NESP). Nephrol Dial Transplant, 2001, 16(suppl 3):14-21.
[7] 程虹,杨思仪,马金伟,等.一种新型高糖基化促红细胞生成素免疫融合蛋白. 中国,CN101870735 A,2010年10月27日. Cheng H, Yang S Y, Ma J W, et al. Manufaction of a New High-glycosylated Fusion Protein. China, CN101870735 A,2010,10,27.
[8] Holm L. Codon usage and gene expression. Nucleic Acids Res, 1986, 14(7):3075-3087.
[9] 汪家政, 范明.蛋白质技术手册.北京:科学出版社,2000.60-120. Wang J Z, Fan M. A Manual of Protein Technology .Beijing :Science Press, 2000.60-120.
[10] Shi X, Yang J, Zhu N, et al. Pharmacokinetics and pharmacodynamics of recombinant human EPO-Fc Fusion protein in vivo. Plos One, 2013 8(7):e72673.
[11] 马金伟,程虹,褚学者,等. 免疫融合蛋白sFcεRIα/mIg(IgG2)的研制. 中国生物工程杂志, 2010,30(10):17-21. Ma J W, Cheng H, Chu X Z, et al. Development of chimera protein: sFcεRIα/mIg (IgG2). China Biotechnology, 2010,30(10):17-21.
[12] Sockolosky J T, Kivimäe S, Szoka F C. Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice. PLoS One, 2014,9(7):e102566.
[13] Hsu D H, Shi J D, Homola M, et al. A humanized anti-CD3 antibody, Hum291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees. Transplantation, 1999, 68(4):545-554.
[14] Fisher J W. Erythropoietin: physiologic and pharmacologic aspects.Proc Soc Exp Biol Med, 1997, 216(3):358-369.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
